Last reviewed 2026-04-20 · How we verify

add-on sirolimus therapy

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhea
• Platelet count decreased
• Nausea
• White blood cell decreased
• Anemia
• Neutrophil count decreased
• Fatigue
• Lymphocyte count decreased
• Hypomagnesemia
• Hypertriglyceridemia
• Hypoalbuminemia
• Hypocalcemia

Key clinical trials

• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
• Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
• PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (PHASE2)
• Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PHASE1, PHASE2)
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (PHASE1, PHASE2)
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (PHASE3)
• Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• add-on sirolimus therapy CI brief — competitive landscape report
• add-on sirolimus therapy updates RSS · CI watch RSS
• Ruijin Hospital portfolio CI